MedTrace Logo

Effects of an Encapsulated Calcium Butyrate Dietary Supplement on Gut Health

NCT06397482 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-05-03

No results posted yet for this study

Summary

The primary objective of this single-arm pilot study is to investigate the effects of an encapsulated calcium butyrate dietary supplement on gastrointestinal (GI) health outcomes in healthy adults, including GI symptom severity (e.g., gas/flatulence and abdominal bloating), bowel habits (frequency and consistency), digestion-associated quality of life, and measures of GI permeability.

Conditions

  • Healthy
  • Gastrointestinal Discomfort

Interventions

DIETARY_SUPPLEMENT

Encapsulated Calcium Butyrate

Contains at minimum 35% butyric acid

Sponsors & Collaborators

  • Kemin Foods LC

    lead INDUSTRY

Principal Investigators

  • Aditi Shah, MD · Biofortis Innovation Services

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-23
Primary Completion
2024-01-23
Completion
2024-01-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06397482 on ClinicalTrials.gov